CN Mobile Logo


Hematologic Malignancies

Hematologic Malignancies

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

A phase II study of the BCL2 inhibitor venetoclax has shown that a large majority of patients with relapsed or refractory chronic lymphocytic leukemia responded to treatment with the drug.

In this article, we elucidate the rationale for use of novel drug combinations in patients with myeloma, and review current evidence-based data supporting the use of specific combinations in various settings. We also attempt to craft a framework to guide clinicians in optimizing the use of combination therapies, to enable patients to derive maximal benefit.

In the past, multiple myeloma was a disease with grim prospects for survival, and few therapeutic options. Today we have a multitude of options, and the armamentarium will continue to expand.

The early 21st century has brought with it significant improvements in survival from most common hematologic malignancies for patients aged 65 years or older, but these increases still lag behind those of 50- to 59-year-olds.

A new study has found an association between body mass index and the risk for multiple myeloma among African Americans in the United States.

Some patients with mantle cell lymphoma may safely defer treatment for their disease, and, in fact, deferral of therapy was an independent predictor of overall survival.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.